Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:11/9/2017
Start Date:July 14, 2017
End Date:July 14, 2021
Contact:Dan Pryma, MD
Email:PennCancerTrials@emergingmed.com
Phone:855-216-0098

Use our guide to learn which trials are right for you!

Men with a history of prostate cancer may be in this study. Subjects recommended for a
prostatectomy or oligometastectomy will undergo PET/CT imaging using a novel radiotracer
[18F]FTT to evaluate PARP-1 activity in known or suspected sites of primary or metastatic
disease. Imaging will be compared with pathology results, including additional research
assays when possible.


Inclusion Criteria:

- Participants will be ≥ 18 years of age

- Biopsy proven prostate cancer

- Must meet one of the following criteria:

1. At least two tissue cores containing at least 50% tumor (per pathology report) OR

2. At least one lesion that is 1 cm or greater in size by standard imaging (e.g.
ultrasound, MRI, CT). Only one type of imaging is required to show a lesion of 1
cm or greater in order for the patient to be eligible to participate in this
study.

- Recommended for clinically indicated radical prostatectomy or oligometastectomy

- Willing to allow use or collection of pathology tissue for the purposes of research
from either clinical biopsy or surgical procedure (if adequate tissue is available)

- Participants must be informed of the investigational nature of this study and be
willing to provide written informed consent and participate in this study in
accordance with institutional and federal guidelines prior to study-specific
procedures.

Exclusion Criteria:

- Inability to tolerate imaging procedures in the opinion of an investigator or treating
physician

- Serious or unstable medical or psychological conditions that, in the opinion of the
investigator, would compromise the subject's safety or successful participation in the
study.

- Only individuals (aged 18 or over) who can understand and give informed consent will
be approached to participate in this study. Individuals who are considered to be
mentally disabled will not be recruited for this study. All subjects must understand
and be able to give informed consent. We will not be using specific methods to assess
decisional capacity. Economically disadvantaged persons will not be vulnerable to
undue influence, as this study offers no compensation. All individuals will be told
that their choice regarding study participation will in no way change their access to
clinical care. This should negate any undue influence or coercion. Women, children,
fetuses, neonates, or prisoners are not included in this research study.
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
(215) 662-6065
Phone: 855-216-0098
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials